NCT01209117View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Infections, Human Immunodeficiency Virus and HerpesviridaeInfection, Human Immunodeficiency Virus
Interventions
DRUG

GSK2248761 WBM Capsule

200 mg GSK2248761 WBM capsule (reference) 2 X100mg

DRUG

GSK2248761 WBM Tablet Formulation 1

GSK2248761 WBM Tablet 200mg manufacturing process 1

DRUG

GSK2248761 WBM Tablet Formulation 2

GSK2248761 WBM Tablet 200mg manufacturing process 2

DRUG

GSK2248761 WBM Tablet Formulation 3

GSK2248761 WBM Tablet 200mg manufacturing process 3

DRUG

GSK2248761 WBM Tablet

GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY